Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

The mTORC2 signaling network: targets and cross-talks

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

mTOR Signaling in Growth Control and Disease

mTORC2: a multifaceted regulator of autophagy

mTORC2: The other mTOR in autophagy regulation

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer

Targeting mTOR globally in cancer: thinking beyond rapamycin.

The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Nutrient regulation of mTORC1 at a glance

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Regulation of mTORC1 by Upstream Stimuli

Cross-talk between Sirtuin and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in the Regulation of S6 Kinase 1 (S6K1) Phosphorylation

Progress in mTOR study

Biochemical and Pharmacological Inhibition of Mtor by Rapamycin and an ATP-Competitive Mtor Inhibitor

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges